These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 37450324)
1. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer. Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324 [TBL] [Abstract][Full Text] [Related]
2. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING). Xie X; Liu J; Wang X Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423 [TBL] [Abstract][Full Text] [Related]
4. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039 [TBL] [Abstract][Full Text] [Related]
5. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751 [TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802 [TBL] [Abstract][Full Text] [Related]
7. STING Activation and its Application in Immuno-Oncology. Lian Y; Duffy KJ; Yang J Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767 [TBL] [Abstract][Full Text] [Related]
8. piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization. Zhuo SH; Wang TY; Zhao L; Su JY; Hu JJ; Zhao YF; Li YM Angew Chem Int Ed Engl; 2024 Sep; 63(38):e202407037. PubMed ID: 38767062 [TBL] [Abstract][Full Text] [Related]
9. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005 [TBL] [Abstract][Full Text] [Related]
10. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. Chang W; Altman MD; Lesburg CA; Perera SA; Piesvaux JA; Schroeder GK; Wyss DF; Cemerski S; Chen Y; DiNunzio E; Haidle AM; Ho T; Kariv I; Knemeyer I; Kopinja JE; Lacey BM; Laskey J; Lim J; Long BJ; Ma Y; Maddess ML; Pan BS; Presland JP; Spooner E; Steinhuebel D; Truong Q; Zhang Z; Fu J; Addona GH; Northrup AB; Parmee E; Tata JR; Bennett DJ; Cumming JN; Siu T; Trotter BW J Med Chem; 2022 Apr; 65(7):5675-5689. PubMed ID: 35332774 [TBL] [Abstract][Full Text] [Related]
11. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144 [TBL] [Abstract][Full Text] [Related]
12. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601 [TBL] [Abstract][Full Text] [Related]
13. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989 [TBL] [Abstract][Full Text] [Related]
14. Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists. Song Z; Wang X; Zhang Y; Gu W; Shen A; Ding C; Li H; Xiao R; Geng M; Xie Z; Zhang A J Med Chem; 2021 Feb; 64(3):1649-1669. PubMed ID: 33470814 [TBL] [Abstract][Full Text] [Related]
15. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration. Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593 [TBL] [Abstract][Full Text] [Related]
18. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Corrales L; Glickman LH; McWhirter SM; Kanne DB; Sivick KE; Katibah GE; Woo SR; Lemmens E; Banda T; Leong JJ; Metchette K; Dubensky TW; Gajewski TF Cell Rep; 2015 May; 11(7):1018-30. PubMed ID: 25959818 [TBL] [Abstract][Full Text] [Related]
19. Design of amidobenzimidazole STING receptor agonists with systemic activity. Ramanjulu JM; Pesiridis GS; Yang J; Concha N; Singhaus R; Zhang SY; Tran JL; Moore P; Lehmann S; Eberl HC; Muelbaier M; Schneck JL; Clemens J; Adam M; Mehlmann J; Romano J; Morales A; Kang J; Leister L; Graybill TL; Charnley AK; Ye G; Nevins N; Behnia K; Wolf AI; Kasparcova V; Nurse K; Wang L; Puhl AC; Li Y; Klein M; Hopson CB; Guss J; Bantscheff M; Bergamini G; Reilly MA; Lian Y; Duffy KJ; Adams J; Foley KP; Gough PJ; Marquis RW; Smothers J; Hoos A; Bertin J Nature; 2018 Dec; 564(7736):439-443. PubMed ID: 30405246 [TBL] [Abstract][Full Text] [Related]
20. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis. Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]